+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
WOCKPHARMA

Wockhardt Share Price

 

 

Wockhardt live price: ₹1854.5. It opened at ₹1,805 vs previous close ₹1,811; intraday high/low: ₹1,878/₹1,792. The 50 & 200 DMA stand at ₹1,800.19/₹1,549.06.

Wockhardt Performance

  • Today's Low
  • ₹1,792
  • Today's High
  • ₹1,878
  • 52 Week Low
  • ₹1,087
  • 52 Week High
  • ₹2,422
  • Open Price₹1,805
  • Previous Close₹1,811
  • Volume717,477
  • 50 DMA₹1,800.19
  • 100 DMA₹1,665.18
  • 200 DMA₹1,549.06

Wockhardt Chart

Investment Returns

  • Over 1 Month -4.31%
  • Over 3 Month + 36.04%
  • Over 6 Month + 33.65%
  • Over 1 Year + 5.54%

Smart Investing Starts Here Start SIP with Wockhardt for Steady Growth!

Invest Now

Wockhardt Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 141.5
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 30,134
  • P/B Ratio
  • 6.1
  • Average True Range
  • 81.35
  • EPS
  • 17.48
  • Dividend Yield
  • 0
  • MACD Signal
  • 29.38
  • RSI
  • 47.08
  • MFI
  • 32.33

Latest Stock News Updates

Looking beyond generics: Wockhardt is showing the way in antibiotics

Wockhardt's FDA-approved Zaynich marks a breakthrough in India's pharmaceutical innovation, offering a new weapon against antimicrobial resistance

Wockhardt targets 50% of revenue from novel drugs within five years

Wockhardt expects novel drugs to contribute over half its revenue within five years as it expands a differentiated antibiotic portfolio built through decades of RD

Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What's behind the selloff?

Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for urinary tract infections. The company also reported a strong turnaround in its March quarter results. Revenue and profit saw significant year-on-year growth. Biotech operations were a key driver of this improved performance.

Wockhardt Financials

Wockhardt Technicals

EMA & SMA

Current Price
₹1,854.50
+ 43.8 (2.42%)
pointer
  • Bearish Moving Average 7
  • Bullish Moving Average 9
  • 20 Day
  • ₹1,892.40
  • 50 Day
  • ₹1,800.20
  • 100 Day
  • ₹1,665.20
  • 200 Day
  • ₹1,549.10

Resistance and Support

1841.6 Pivot Speed
  • R3 1,976.30
  • R2 1,927.10
  • R1 1,890.80
  • S1 1,805.30
  • S2 1,756.10
  • S3 1,719.80

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Wockhardt Ltd. is a global pharmaceutical and biotechnology company specializing in the development, manufacturing, and marketing of medicines, vaccines, and biosimilars. It focuses on key therapeutic areas including anti-infectives, cardiology, and diabetes care.

Wockhardt has an operating revenue of Rs. 3,373.00 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 7% is okay, ROE of 4% is fair but needs improvement. The company has a reasonable debt to equity of 31%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 22% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around 1% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 68 which is a FAIR score but needs to improve its earnings, a RS Rating of 83 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 40 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Wockhardt Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-04 Audited Results & Others Inter-alia, to consider 1. Raising of funds by issue of Equity Shares, American Depository Receipts , Foreign Currency Convertible Bonds or any combination thereof or any other method. issue of equity shares of Rs. 5/- each in the ratio of 3:10 @ premium of Rs. 220/-.
2026-02-10 Quarterly Results
2025-11-03 Quarterly Results
2025-08-08 Quarterly Results
2025-05-29 Audited Results & Fund Raising

Wockhardt Shareholding Pattern

49.08%
8.12%
0.06%
7.09%
0%
25.9%
9.75%

Wockhardt FAQs

Wockhardt share price is ₹1,854 As on 14 July, 2026 | 07:34

The Market Cap of Wockhardt is ₹30134.2 Cr As on 14 July, 2026 | 07:34

The P/E ratio of Wockhardt is 141.5 As on 14 July, 2026 | 07:34

The PB ratio of Wockhardt is 6.1 As on 14 July, 2026 | 07:34

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23